1,967 pharmaceutical and medication recalls tracked. Stay informed about FDA drug safety alerts, prescription medications, over-the-counter drugs, and dietary supplements.
Looking for a specific drug? Use the search page to find recalls by medication name, manufacturer, or NDC number.
Biocon Pharma Inc. recalled 28,157 bottles of PRAZOSIN HYDROCHLORIDE capsules, distributed nationwide in the USA. The recall cites cGMP deviation due to detection of N-nitroso-prazosin impurity C above acceptable limits. Stop using the product immediately and contact Appco Pharma LLC or your healthcare provider for guidance.
Biocon Pharma Inc. recalled 58,896 bottles of Prazosin Hydrochloride Capsules, USP, 2 mg, 100-count bottle. The product was distributed nationwide in the USA and manufactured by Appco Pharma LLC. A cGMP deviation detected N-nitroso-prazosin impurity C above acceptable limits. Consumers and healthcare providers should stop using this product immediately and contact Appco Pharma LLC or their health‑
Discoloration: Firm received five (5) complaints stating that, "Tablets discolored darker than normal and have lighter-colored spots."
Bioenrrty recalled MPINOI branded adult portable bed rails sold on Amazon after reports of serious entrapment and potential asphyxiation. The recall cites a violation of a mandatory standard and missing hazard warnings. Consumers should stop using the product immediately and seek a full refund.
Vive Health recalled adult portable bed rails after two deaths were linked to entrapment and asphyxiation. The recall covers the Compact Bed Rail model LVA2009SLV, Bed Rail Collection V model LVA2097SLV, and LVA1024 units purchased on or before August 21, 2023. A prior recall covered LVA1024 units purchased after that date. Consumers must stop using these rails and seek a full refund from Vive.
Geri-Care eye drops recalled nationwide after lack of sterility assurance affects 720 bottles. The product, ARTIFICIAL TEARS with NDC 68788-7266-0, is manufactured by Preferred Pharmaceuticals, Inc. in Brooklyn, NY. The FDA recall class II points to a risk of contamination. Stop using immediately and contact a healthcare provider for guidance.
Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.
Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.
Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.
Failed Dissolution Specifications
GE Healthcare recalled Omnipaque iohexol injection, 300 mg/mL, distributed nationwide in the United States. The Class II recall covers 866,570 vials due to particulate matter. Healthcare providers should stop use and contact GE Healthcare Ireland Limited for guidance.
GE Healthcare recalled Omnipaque iohexol injection after discovery of particulate matter. The recall covers 306,810 vials distributed nationwide in the United States. WHS: Distributed by GE Healthcare Inc., Marlborough, MA. Consumers should stop use and consult a healthcare provider for guidance.
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Fagron Compounding Services recalled 34,260 bags of Vancomycin HCI Injection across the United States. The recall cites lack of sterility assurance and a blue Break-Off-Part that could detach from the administration port. Healthcare providers and patients should stop using the product immediately and follow manufacturer guidance.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
Receive immediate notifications when medications you care about are recalled. Stay safe with timely FDA drug safety alerts.